What are Antiparasitic combination drugs?

Antiparasitic combination drugs are pharmacologic agents that share a common mechanism (typically targeting Leishmania cell membrane and ribosomal protein synthesis). 0 are currently marketed, with 3 more in clinical development.

Antiparasitic combination

0 marketed 3 in Phase 3

This page covers all Antiparasitic combination drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Leishmania cell membrane and ribosomal protein synthesis, Glutamate-gated chloride channels (ivermectin); beta-tubulin (albendazole), GABA-gated chloride channels (ivermectin); β-tubulin (albendazole); microfilarial motility (DEC).

Targets

Leishmania cell membrane and ribosomal protein synthesis · Glutamate-gated chloride channels (ivermectin); beta-tubulin (albendazole) · GABA-gated chloride channels (ivermectin); β-tubulin (albendazole); microfilarial motility (DEC)

Phase 3 pipeline (3)

Miltefosine and Paromomycin · Drugs for Neglected Diseases · Infectious Disease / Neglected Tropical Diseases
Miltefosine disrupts parasite cell membranes while paromomycin inhibits protein synthesis, together providing synergistic activity against Leishmania parasites.
IVM plus ALB · University Hospitals Cleveland Medical Center · Infectious Disease / Parasitology
IVM (ivermectin) and ALB (albendazole) are antiparasitic agents that work synergistically to paralyze and kill parasitic worms by disrupting their neuromuscular function.
IDA - Ivermectin + DEC + albendazole · Medicines Development for Global Health · Infectious Disease / Parasitology
IDA is a triple-drug combination that paralyzes and kills parasitic worms through multiple mechanisms: ivermectin and DEC (diethylcarbamazine) target neuromuscular function in microfilariae, while albendazole disrupts microtubule formation in helminths.